Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Hana Biosciences Charts. Click Here for more Hana Biosciences Charts.](/p.php?pid=staticchart&s=A%5EHBX&p=8&t=15)
Hana Biosciences (AMEX:HBX), a biopharmaceutical company
focused on advancing cancer care, received approval of its application
to list its common shares on the NASDAQ National Market. Hana's common
shares will begin trading on NASDAQ on Monday, April 17, 2006 under
the symbol HNAB. The trading of Hana's shares on the American Stock
Exchange will cease on the close of business on Thursday, April 13,
2006.
"Reaching a NASDAQ National Market listing is another important
step forward in the development of Hana," said John Iparraguirre, Vice
President and Chief Financial Officer, Hana Biosciences. "We are
excited about this important milestone and believe that current and
future shareholders will benefit from the enhanced profile this
listing provides Hana."
About Hana Biosciences
Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco,
CA-based biopharmaceutical company that acquires, develops, and
commercializes innovative products to advance cancer care. The company
is committed to creating value by building a world-class team,
accelerating the development of lead product candidates, expanding its
pipeline by being the alliance partner of choice, and nurturing a
unique company culture. Additional information on Hana Biosciences can
be found at www.hanabiosciences.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements involve risks and uncertainties that could cause Hana's
actual results to differ materially from the anticipated results and
expectations expressed in these forward-looking statements. These
statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties, which could
cause actual outcomes and results to differ materially from these
statements. Among other things, there can be no assurances that any of
Hana's development efforts relating to its product candidates will be
successful. Other risks that may affect forward-looking information
contained in this press release include the possibility of being
unable to obtain regulatory approval of Hana's product candidates, the
risk that the results of clinical trials may not support Hana's
claims, Hana's reliance on third-party researchers to develop its
product candidates, and its lack of experience in developing
pharmaceutical products. Additional risks are described in the
company's Annual Report on Form 10-K for the year ended Dec. 31, 2005.
Hana assumes no obligation to update these statements, except as
required by law.